EW LAWSUIT NEWS: The December 13 Deadline in Edwards Lifesciences Securities Fraud Class Action is Approaching; Contact BFA Law if You Lost Money (NYSE:EW)

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that the company failed to reach the low-treatment-rate population and that healthcare organizations prioritized other treatments [2]. - On July 24, 2024, Edwards Lifesciences reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for TAVR in fiscal Q2 2024, leading to a 31% decline in stock price from $86.95 to $59.70 per share [3]. Group 2: Company Background - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, categorizing its products into four main areas: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart therapies, and Critical Care therapies [2].